Marengo Therapeutics Shares Promising Results on Cancer Therapy at 2025 Conference Marengo Therapeutics presents early findings on the combination of Invikafusp Alfa and TRODELVY® for breast cancer, showing promising results in terms of safety and anti-tumor activity.

Marengo Therapeutics Shares Promising Results on Cancer Therapy at 2025 Conference #United_States #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #Trodelvy

Marengo's Invikafusp Alfa Shows Promise in PD-1-Resistant Cancers at SITC 2025 During SITC 2025, Marengo's Invikafusp alfa demonstrated significant activity in PD-1-resistant cancers, achieving 20% ORR and 80% DCR in TMB-H tumors.

Marengo's Invikafusp Alfa Shows Promise in PD-1-Resistant Cancers at SITC 2025 #United_States #Cambridge #Invikafusp_Alfa #Marengo #TMB-H

Marengo Therapeutics to Present Promising Results of Invikafusp Alfa at SITC 2025 Meeting Marengo Therapeutics will debut critical findings about Invikafusp Alfa's immunotherapy effectiveness for TMB-High cancer at SITC 2025.

Marengo Therapeutics to Present Promising Results of Invikafusp Alfa at SITC 2025 Meeting #USA #National_Harbor #Marengo_Therapeutics #Invikafusp_Alfa #STARt-001

Marengo's Phase 2 Findings Showcase Invikafusp Alfa's Potential as a New Immunotherapy Marengo Therapeutics recently unveiled significant Phase 2 trial outcomes for Invikafusp Alfa, highlighting impressive efficacy in treating PD-1 resistant tumors. A new hope in immunotherapy emerges.

Marengo's Phase 2 Findings Showcase Invikafusp Alfa's Potential as a New Immunotherapy #USA #Cambridge #Immunotherapy #Marengo_Therapeutics #Invikafusp_Alfa

Marengo's Invikafusp Alfa Shows Promise in Late-Breaking ESMO Presentation Marengo Therapeutics presented promising data on Invikafusp alfa’s monotherapy for PD-1 resistant GI tumors at the ESMO 2025 Congress, highlighting significant response rates.

Marengo's Invikafusp Alfa Shows Promise in Late-Breaking ESMO Presentation #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #PD-1_Resistant

Marengo Therapeutics Enhances Scientific Advisory Board with Dr. Everett Vokes Amid Advancements in Clinical Oncology Marengo Therapeutics announces the addition of Dr. Everett Vokes to their Scientific Advisory Board, enhancing efforts in precision oncology with Invikafusp alfa.

Marengo Therapeutics Enhances Scientific Advisory Board with Dr. Everett Vokes Amid Advancements in Clinical Oncology #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #Dr._Everett_Vokes

Marengo Therapeutics Initiates Clinical Trial with Invikafusp Alfa and Trodelvy for Breast Cancer Marengo Therapeutics has initiated its STARt-002 trial for metastatic breast cancer, assessing the innovative Invikafusp Alfa alongside Trodelvy®, aiming to expand immunotherapy options.

Marengo Therapeutics Initiates Clinical Trial with Invikafusp Alfa and Trodelvy for Breast Cancer #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #Trodelvy

Marengo Unveils Promising Results for Invikafusp Alfa Against PD-1 Resistant Cancers at AACR 2025 Marengo Therapeutics presents significant findings on Invikafusp Alfa's efficacy in targeting PD-1 resistant tumors at AACR 2025, showcasing durable disease control.

Marengo Unveils Promising Results for Invikafusp Alfa Against PD-1 Resistant Cancers at AACR 2025 #United_States #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #AACR_2025

Marengo Therapeutics to Reveal New Invikafusp Alfa Data at AACR 2025 Conference Marengo Therapeutics announces it will present significant clinical updates on invikafusp alfa at AACR 2025, highlighting its potential in PD1-resistant tumors.

Marengo Therapeutics to Reveal New Invikafusp Alfa Data at AACR 2025 Conference #United_States #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #AACR_2025

Marengo Therapeutics to Spotlight Innovations at Annual J.P. Morgan Healthcare Conference Marengo Therapeutics will showcase its groundbreaking T cell activation approaches at the J.P. Morgan Healthcare Conference, highlighting recent clinical advancements.

Marengo Therapeutics to Spotlight Innovations at Annual J.P. Morgan Healthcare Conference #United_States #Cambridge #J.P._Morgan #Marengo_Therapeutics #Invikafusp_Alfa

Marengo's Invikafusp Alfa Gains FDA Fast Track Status for Colorectal Cancer Treatment Marengo Therapeutics announces that its novel treatment, Invikafusp Alfa, receives Fast Track designation from the FDA for colorectal cancer therapy.

Marengo's Invikafusp Alfa Gains FDA Fast Track Status for Colorectal Cancer Treatment #United_States #Cambridge #FDA_Fast_Track #Invikafusp_Alfa #Marengo

Marengo Therapeutics Begins Phase 2 Trials for Invikafusp Alfa Across Europe Marengo Therapeutics announces the start of Phase 2 clinical trials for Invikafusp Alfa, targeting PD-1 resistant tumors in Europe, featuring promising results from earlier studies.

Marengo Therapeutics Begins Phase 2 Trials for Invikafusp Alfa Across Europe #USA #Cambridge #Marengo_Therapeutics #Invikafusp_Alfa #STARt-001